SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Subscribe To Our Newsletter & Stay Updated
